Tolperisone Use in Heart Failure Patients

Evidence-Based Rationale

• The European Society of Cardiology recommends monitoring of blood pressure, renal function, and potassium levels when prescribing ACE inhibitors to heart failure patients, with a follow-up assessment at 1-2 weeks after initiation and dose changes 1, 2, 5
• The American Heart Association suggests that beta-blockers require monitoring of heart rate, blood pressure, and clinical status during titration in heart failure patients 4, 6
• The European Society of Cardiology guidelines indicate that diuretics and spironolactone require monitoring of electrolytes and renal function, particularly potassium levels, in heart failure patients 3

Key Considerations for Safe Use

• The American College of Cardiology recommends verifying heart failure medication stability before initiating tolperisone, ensuring patients are on stable doses of guideline-directed medical therapy (ACE inhibitor/ARB, beta-blocker, diuretics) 5, 6
• The European Society of Cardiology suggests checking baseline parameters, including blood pressure, heart rate, and stable renal function, before initiating tolperisone in heart failure patients 1, 4, 5
• The American Heart Association advises against discontinuing or reducing guideline-directed medical therapy (ACE inhibitors, beta-blockers, spironolactone) to accommodate tolperisone, as these medications provide proven mortality benefit in heart failure 5, 6